Intrepida: Tackling the innate immune system to treat cancer

Intrepida Bio is developing first-in-class mAbs against BAG3 to modulate the TME

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer.

The company hopes the target will be a differentiator in the already crowded immuno-oncology space.

Sofinnova Investments and Canaan Partners co-led the financing round with participation from Indaco Venture Partners and Vertis SGR.

Intrepida Bio Inc. is founded on work

Read the full 735 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE